Shire PLC (ADR) (SHPG) was Downgraded by HSBC Securities to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. HSBC Securities advised their investors in a research report released on Sep 26, 2016.
On the company’s financial health, Shire PLC (ADR) reported $3.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $3.09. The company had revenue of $2429.00 million for the quarter, compared to analysts expectations of $2275.68 million. The company’s revenue was up 55.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.63 EPS.
Shire PLC (ADR) opened for trading at $204.4 and hit $205.13 on the upside on Thursday, eventually ending the session at $204.22, with a gain of 0.11% or 0.22 points. The heightened volatility saw the trading volume jump to 13,54,199 shares. Company has a market cap of $61,280 M.
Shire plc is a biopharmaceutical company. The Company along with its subsidiaries is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience Gastrointestinal (GI) Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate) ADDERALL XR (mixed salts of a single-entity amphetamine) INTUNIV (extended release guanfacine) EQUASYM (methylphenidate hydrochloride) modified release (XL) BUCCOLAM LIALDA (mesalamine)/ MEZAVANT(mesalazine) PENTASA (mesalamine) RESOLOR (prucalopride) REPLAGAL (agalsidase alfa) VPRIV (velaglucerase alfa) FIRAZYR (icatibant) CINRYZE C1 esterase inhibitor (human) FOSRENOL (lanthanum carbonate) XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).